Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center

home / authors / krina-k-patel-md-msc-university-of-texas-md-anderson-cancer-center

Articles

Dr Patel on the Efficacy of Ide-Cel in Patients With High-Risk R/R Multiple Myeloma

June 19th 2023

Krina K. Patel, MD, MSc, discusses the effect of high-risk features on outcomes with ide-cel in triple-class–exposed, relapsed/refractory multiple myeloma.

Unmet Needs and Future Perspectives in Multiple Myeloma Care

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

March 13th 2023

The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.

Does Belantamab Have a Place in Multiple Myeloma Treatment?

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

March 13th 2023

The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.

Preventing Infection in Patients with Multiple Myeloma During Treatment

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

March 13th 2023

Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.

Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

March 6th 2023

Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.

Targets in Multiple Myeloma: FcRH5

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

March 6th 2023

Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.

Targets in Multiple Myeloma: GPRC5D

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 27th 2023

Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.

Data Updates on Immunotherapy Combinations in Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 27th 2023

Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.

Retreatment with a BCMA-Targeting Bispecific for R/R MM

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 20th 2023

Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.

$BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma$

BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 20th 2023

Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.

CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 13th 2023

The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.

Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 13th 2023

Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.

Quadruplet Combination Therapies in Relapsed Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 6th 2023

Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.

Strategies for Treatment of Multiple Myeloma at Late Relapse

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 6th 2023

The panel debates the options for treatment of late relapsed multiple myeloma.

Data Updates in the Treatment of Relapsed Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

January 30th 2023

Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.

Relapse in Multiple Myeloma: Biochemical and Chemical

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

January 30th 2023

Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

January 23rd 2023

Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.

Defining Frailty in Multiple Myeloma for Optimal Treatment

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

January 23rd 2023

Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

Unmet Needs in the Treatment of NDMM and R/R MM and Clinical Pearls for Community Oncologists

Shaji Kumar, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center

January 17th 2023

The panel closes their discussion by highlighting unmet needs in the multiple myeloma treatment landscape and sharing advice for physicians and patients.

Treatment Options for MM at Early Relapse

Shaji Kumar, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center

January 17th 2023

Krina Patel, MD, explains the treatment options for patients with early relapsed multiple myeloma.

Key Considerations for Patients with Multiple Myeloma During the Treatment Journey

Shaji Kumar, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center

January 10th 2023

Jenny Ahlstrom, a patient with multiple myeloma, shares considerations for patients going through treatment, including toxicities, follow-up, and travel planning.

Available Induction Treatment Regimens for Patients with Transplant-Ineligible MM

Shaji Kumar, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center

January 10th 2023

Shaji Kumar, MD, and Krina Patel, MD, discuss the treatment options for patients with newly-diagnosed multiple myeloma who are not eligible for stem cell transplant.

Optimal Treatment Selection for Patients with NDMM: Updates from IMS 2022

Shaji Kumar, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center

January 3rd 2023

Dr Krina Patel discusses updates in the treatment of newly-diagnosed from recent meetings how the appropriate treatments are selected in patients with newly-diagnosed multiple myeloma.

The Role of Stem Cell Transplant in the NDMM Treatment Landscape

Shaji Kumar, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center

January 3rd 2023

Dr Shaji Kumar reviews clinical trial data on the role of stem cell transplant as a treatment for newly-diagnosed multiple myeloma in tandem with a multi-agent combination therapy.

Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

December 22nd 2022

Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.

Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

December 22nd 2022

Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.

Induction Regimen Options for Patients with Transplant-Eligible Newly-Diagnosed Multiple Myeloma (NDMM)

Shaji Kumar, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center

December 19th 2022

Krina Patel, MD, details the three- and four-drug regimen first-line treatment options for transplant-eligible newly-diagnosed multiple myeloma and how to make an appropriate treatment decision.

Introduction to Multiple Myeloma and Resources for Patient Education after Diagnosis

Shaji Kumar, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center

December 19th 2022

Shaji Kumar, MD, provides an overview of multiple myeloma, and Jenny Ahlstrom, a patient with multiple myeloma, shares the story of her diagnosis and the resources she used to educate herself.

Improving Care in Multiple Myeloma: Unmet Needs and Future Directions

Ajai Chari, MD, PhD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Cristina Gasparetto, MD, Duke Cancer Institute;Rafael Fonseca, MD;Omar Nadeem, MD

August 25th 2022

Closing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.